Chronic Graft Versus Host Disease Clinical Trial
Official title:
A Phase II Trial of Bortezomib (Velcade) Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
The purpose of this research study is to determine the effectiveness of bortezomib (Velcade) plus prednisone for treating chronic graft versus host disease (cGVHD) and the safety of this drug combination in this patient population. Chronic GVHD is a medical condition that may occur after allogeneic stem cell transplantation. The donor's immune system may recognize the participants body (the host) as foreign and attempt to "reject" it. Bortezomib has been used in other research studies, and information from those studies suggests that this drug may help to control the abnormal immune responses that underlie cGVHD.
- Each treatment cycle lasts five weeks, during which time participants will come to the
clinic to receive bortezomib intravenously once a week for the first 4 weeks.
Prednisone will be taken orally on a daily basis and dose reduction may be initiated
after 1 cycle of therapy.
- During all treatment cycles, participants will have the following: physical exam and
blood work. At the end of cycle 3 (week 15) the participants cGVHD will be evaluated.
These assessments may include an eye examination, a skin examination, a pulmonary
function test and/or, a flexion assessment test.
- Participants will receive 3 cycles of bortezomib.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
| Terminated |
NCT02337517 -
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
|
Phase 2 | |
| Terminated |
NCT02461134 -
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
|
Phase 2 | |
| Recruiting |
NCT03839069 -
Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis
|
N/A | |
| Active, not recruiting |
NCT00637689 -
Improving Outcomes Assessment in Chronic GVHD
|
||
| Not yet recruiting |
NCT06233110 -
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
|
Phase 1 | |
| Active, not recruiting |
NCT01937468 -
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
|
Phase 1 | |
| Completed |
NCT01810718 -
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD
|
Phase 1 | |
| Completed |
NCT01380535 -
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
|
Early Phase 1 | |
| Terminated |
NCT01964625 -
Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)
|
N/A | |
| Active, not recruiting |
NCT03790332 -
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
|
Phase 1/Phase 2 | |
| Completed |
NCT01680965 -
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT02491359 -
Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
|
Phase 2 | |
| Recruiting |
NCT06300320 -
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
|
Phase 2 | |
| Recruiting |
NCT05922761 -
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
|
Phase 2 | |
| Terminated |
NCT02701634 -
Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
|
Phase 2 | |
| Recruiting |
NCT06247150 -
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
|
N/A | |
| Active, not recruiting |
NCT04212416 -
Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease
|
Phase 1 | |
| Completed |
NCT02959944 -
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
|
Phase 3 | |
| Completed |
NCT01954979 -
Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)
|
Phase 1 |